{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:30:40Z","timestamp":1785403840530,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is a well-recognised treatment option for the management of colorectal peritoneal metastases (CRPM). However, incorporating the routine use of neoadjuvant chemotherapy (NAC) into this management plan is controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic review and meta-analysis were conducted to evaluate the impact of neoadjuvant chemotherapy on perioperative morbidity and mortality, and long-term survival of patients with CRPM undergoing CRS and HIPEC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twelve studies met the inclusion criteria (<jats:italic>n<\/jats:italic> = 2,463 patients). Ten were retrospective cohort, one was prospective cohort, and one was a prospective randomised by design. Patients who received NAC followed by CRS and HIPEC experienced no difference in major perioperative morbidity and mortality compared with patients who underwent surgery first (SF). There was no difference in overall survival at 3 years, but at 5 years NAC patients had superior survival (relative risk [RR] 1.31; 95% confidence interval [CI] 1.11\u20131.54, <jats:italic>P<\/jats:italic> &lt; 0.001). There were no differences in 1- and 3-year, disease-free survival (DFS) between groups. Study heterogeneity was generally high across all outcome measures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients who received neoadjuvant chemotherapy did not experience any increase in perioperative morbidity or mortality. The potential improvement in 5-year overall survival in patients receiving NAC is based on limited confidence due to several limitations in the data, but not sufficiently enough to curtail its use. The practice of NAC in this setting will remain heterogeneous and guided by retrospective evidence until prospective, randomised data are reported.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-11699-7","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T23:03:32Z","timestamp":1649545412000},"page":"6619-6631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis"],"prefix":"10.1245","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-8343","authenticated-orcid":false,"given":"Michael P.","family":"Flood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C. H.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasmira","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peadar S.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish K.","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Heriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"issue":"12","key":"11699_CR1","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","volume":"17","author":"J Franko","year":"2016","unstructured":"Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709\u201319.","journal-title":"Lancet Oncol."},{"key":"11699_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2016.07.002","volume":"65","author":"LG Razenberg","year":"2016","unstructured":"Razenberg LG, Lemmens VE, Verwaal VJ, et al. Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: Results of a population-based study. Eur J Cancer. 2016;65:113\u201320.","journal-title":"Eur J Cancer."},{"issue":"7","key":"11699_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1097\/DCR.0000000000000149","volume":"57","author":"D Baratti","year":"2014","unstructured":"Baratti D, Kusamura S, Iusco D, et al. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum. 2014;57(7):858\u201368.","journal-title":"Dis Colon Rectum."},{"issue":"2","key":"11699_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/jso.24290","volume":"114","author":"IS Froysnes","year":"2016","unstructured":"Froysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016;114(2):222\u20137.","journal-title":"J Surg Oncol."},{"issue":"4","key":"11699_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/jso.24911","volume":"117","author":"MA Kozman","year":"2018","unstructured":"Kozman MA, Fisher OM, Rebolledo BJ, et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study. J Surg Oncol. 2018;117(4):725\u201336.","journal-title":"J Surg Oncol."},{"issue":"3","key":"11699_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1245\/s10434-015-4914-4","volume":"23","author":"M Maillet","year":"2016","unstructured":"Maillet M, Glehen O, Lambert J, et al. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol. 2016;23(3):863\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"11699_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol."},{"issue":"3","key":"11699_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1245\/s10434-016-5712-3","volume":"24","author":"K Waite","year":"2017","unstructured":"Waite K, Youssef H. The role of neoadjuvant and adjuvant systemic chemotherapy with cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review. Ann Surg Oncol. 2017;24(3):705\u201320.","journal-title":"Ann Surg Oncol."},{"key":"11699_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.critrevonc.2017.03.028","volume":"114","author":"KP Rovers","year":"2017","unstructured":"Rovers KP, Simkens GA, Punt CJ, van Dieren S, Tanis PJ, de Hingh IH. Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review. Crit Rev Oncol Hematol. 2017;114:53\u201362.","journal-title":"Crit Rev Oncol Hematol."},{"key":"11699_CR10","unstructured":"Rovers KP, Bakkers C, Simkens G, et al. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6). Bmc Cancer. 2019;19."},{"key":"11699_CR11","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","DOI":"10.1136\/bmj.b2535"},{"issue":"1","key":"11699_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12957-021-02255-w","volume":"19","author":"S Zhou","year":"2021","unstructured":"Zhou S, Jiang Y, Liang J, Pei W, Zhou Z. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. World J Surg Oncol. 2021;19(1):151.","journal-title":"World J Surg Oncol."},{"issue":"9","key":"11699_CR13","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1245\/s10434-016-5214-3","volume":"23","author":"RA Devilee","year":"2016","unstructured":"Devilee RA, Simkens GA, van Oudheusden TR, et al. Increased survival of patients with synchronous colorectal peritoneal metastases receiving preoperative chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(9):2841\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"11699_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials."},{"key":"11699_CR15","unstructured":"GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses."},{"key":"11699_CR16","doi-asserted-by":"crossref","unstructured":"Beal EW, Suarez-Kelly LP, Kimbrough CW, et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9(3).","DOI":"10.3390\/jcm9030748"},{"issue":"9","key":"11699_CR17","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1245\/s10434-014-3713-7","volume":"21","author":"W Ceelen","year":"2014","unstructured":"Ceelen W, Van Nieuwenhove Y, Vande Putte D, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Annals of Surgical Oncology. 2014;21(9):3023\u20138.","journal-title":"Annals of Surgical Oncology."},{"issue":"1","key":"11699_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/SLA.0b013e318255486a","volume":"256","author":"G Passot","year":"2012","unstructured":"Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256(1):125\u20139.","journal-title":"Ann Surg."},{"key":"11699_CR19","unstructured":"Rovers KP, Bakkers C, Nienhuijs SW, et al. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial. JAMA Surg. 2021."},{"issue":"16","key":"11699_CR20","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284\u201392.","journal-title":"J Clin Oncol."},{"issue":"5","key":"11699_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/DCR.0000000000000774","volume":"60","author":"WJ van Eden","year":"2017","unstructured":"van Eden WJ, Kok NF, Jozwiak K, et al. Timing of systemic chemotherapy in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Dis Colon Rectum. 2017;60(5):477\u201387.","journal-title":"Dis Colon Rectum."},{"issue":"1","key":"11699_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-018-1554-8","volume":"17","author":"M Leimkuhler","year":"2019","unstructured":"Leimkuhler M, Hemmer PHJ, Reyners AKL, et al. Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study. World J Surg Oncol. 2019;17(1):14.","journal-title":"World J Surg Oncol."},{"issue":"7","key":"11699_CR23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ejso.2021.01.018","volume":"47","author":"DJ Repullo","year":"2021","unstructured":"Repullo DJ, Barbois S, Leonard D, et al. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. Eur J Surg Oncol. 2021;47(7):1661\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"11699_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138.","journal-title":"J Clin Oncol."},{"issue":"6","key":"11699_CR25","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1245\/s10434-013-3442-3","volume":"21","author":"C Eveno","year":"2014","unstructured":"Eveno C, Passot G, Goere D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21(6):1792\u2013800.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"11699_CR26","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1245\/s10434-020-09330-8","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, Rousset P, Benzerdjeb N, et al. Clinical and radiologic predictors of a pathologic complete response to neoadjuvant chemotherapy (NACT) in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: results of a prospective multi-center study. Ann Surg Oncol. 2021;28(7):3840\u20139.","journal-title":"Ann Surg Oncol."},{"key":"11699_CR27","doi-asserted-by":"crossref","unstructured":"Mor E, Assaf D, Laks S, et al. Ratio of pathological response to preoperative chemotherapy in patients undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer correlates with survival. Ann Surg Oncol. 2021.","DOI":"10.1245\/s10434-021-10367-6"},{"key":"11699_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.suronc.2020.02.014","volume":"33","author":"A Taibi","year":"2020","unstructured":"Taibi A, Lo Dico R, Kaci R, Naneix AL, Mathonnet M, Pocard M. Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG. Surg Oncol. 2020;33:158\u201363.","journal-title":"Surg Oncol."},{"issue":"7","key":"11699_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/codi.14106","volume":"20","author":"JC Kong","year":"2018","unstructured":"Kong JC, Guerra GR, Warrier SK, et al. Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis. Colorectal Dis. 2018;20(7):574\u201385.","journal-title":"Colorectal Dis."},{"issue":"8","key":"11699_CR30","doi-asserted-by":"publisher","first-page":"e202701","DOI":"10.1001\/jamaoncol.2020.2701","volume":"6","author":"KP Rovers","year":"2020","unstructured":"Rovers KP, Bakkers C, van Erning FN, et al. Adjuvant systemic chemotherapy vs active surveillance following up-front resection of isolated synchronous colorectal peritoneal metastases. JAMA Oncol. 2020;6(8):e202701.","journal-title":"JAMA Oncol."},{"key":"11699_CR31","doi-asserted-by":"crossref","unstructured":"Ljunggren M, Nordenvall C, Palmer G. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases. Eur J Surg Oncol. 2021.","DOI":"10.1016\/j.ejso.2021.05.046"},{"issue":"5","key":"11699_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.surge.2020.08.016","volume":"19","author":"M Flood","year":"2021","unstructured":"Flood M, Narasimhan V, Waters P, et al. Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review and discussion of latest controversies. Surgeon. 2021;19(5):310\u201320.","journal-title":"Surgeon."},{"issue":"12","key":"11699_CR33","doi-asserted-by":"publisher","first-page":"7476","DOI":"10.1245\/s10434-021-09837-8","volume":"28","author":"JC Kong","year":"2021","unstructured":"Kong JC, Soucisse M, Michael M, et al. Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes. Ann Surg Oncol. 2021;28(12):7476\u201386.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11699-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:11:10Z","timestamp":1663773070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["11699"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11699-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"29 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest. There is no grant support or financial relationship associated with this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}